| Medication | Monthly Cost (2026) | Mechanism | Avg Weight Loss | |-----------|-------------------|-----------|-----------------| | Retatrutide (compounded) | $200650 | Triple agonist (GLP-1/GIP/glucagon) | 24% | | Wegovy (semaglutide) | $1,300+ | GLP-1 only | 15% | | Zepbound (tirzepatide) | $1,059+ | Dual agonist (GLP-1/GIP) | 21% | | Mounjaro (tirzepatide) | $1,023+ | Dual agonist (GLP-1/GIP) | 21% | | Ozempic (semaglutide) | $935+ | GLP-1 only | 12-14% | *Note: Compounded retatrutide prices reflect direct pharmacy costs with valid prescription
The article names significant kidney or liver disease, diabetic retinopathy, and active gallbladder disease as needing careful evaluation before starting, on top of the contraindications it lists: personal or family history of medullary thyroid cancer and multiple endocrine neoplasia syndrome type 2
Whats the difference between retatrutide and Mounjaro
No GLP-1 receptor agonist currently has FDA approval for treating binge eating disorder
Understanding these differences helps clinicians and patients make informed treatment decisions
While side effects occur from taking such drugs, the potential benefits outweigh any risks if taken as prescribed by a health care professional